Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol
Open Access
- 23 May 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 56 (1) , 186-189
- https://doi.org/10.1093/jac/dki170
Abstract
Background: Treatment failure during highly active antiretroviral therapy (HAART) is ultimately common and associated with the development of resistance mutations. Trizivir (zidovudine/lamivudine/abacavir) and tenofovir disoproxil fumarate may improve adherence and enhance virological suppression in individuals who have failed previous regimens. Methods: Individuals were identified who had failed previous HAART and who were then prescribed trizivir and tenofovir. Viral load and genotypic information were obtained to assess virological response. Results: One hundred and twenty-two individuals were identified from a database containing 5883 patients. In a last observation carried forward intention to treat analysis, 34% of individuals achieved an undetectable viral load of P = 0.03). Using the mean cell volume as a measure of compliance, those with higher values were more likely to achieve a viral load P = 0.04). A beneficial effect on cholesterol was noted regardless of virological outcome. Conclusions: In compliant heavily pre-treated individuals with less than 2 TAMs, salvage therapy with trizivir and tenofovir is associated with suppression of viraemia and an improved lipid profile.Keywords
This publication has 26 references indexed in Scilit:
- Where Does HIV Live?New England Journal of Medicine, 2004
- Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individualsAIDS, 2003
- T Cell Dynamics in HIV-1 InfectionAnnual Review of Immunology, 2003
- Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor for the treatment of HIV infectionClinical Therapeutics, 2002
- Increasing Choices for HIV TherapyNew England Journal of Medicine, 2002
- HIV preferentially infects HIV-specific CD4+ T cellsNature, 2002
- Quality of Life, Emotional Status, and Adherence of HIV-1–Infected Patients Treated With Efavirenz Versus Protease Inhibitor–Containing RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Antiviral BriefsAIDS Patient Care and STDs, 2000
- Strategies for long-term success in the treatment of HIV infection.JAMA, 2000
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998